New CAR-T therapy takes on tough rheumatoid arthritis in Head-to-Head trial
NCT ID NCT06475495
First seen Mar 17, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tests a new treatment called CAR-T cell therapy against a standard drug, rituximab, in people with active rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if CAR-T cells are safe and can reduce harmful antibodies linked to the disease. Thirteen participants will receive either a single dose of CAR-T cells or two doses of rituximab, and be followed for one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.